SUPN
Supernus Pharmaceuticals Inc
$
45.400
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
45.530
Open
44.440
VWAP
45.03
Vol
195.65K
Mkt Cap
2.55B
Low
44.280
Amount
8.81M
EV/EBITDA(TTM)
16.81
Total Shares
54.97M
EV
2.27B
EV/OCF(TTM)
31.54
P/S(TTM)
3.68
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
208.85M
+26.23%
0.795
-12.22%
192.18M
+28.27%
0.510
+16.89%
195.48M
+12.24%
0.520
-5.16%
Estimates Revision
The market is revising Upward the revenue expectations for Supernus Pharmaceuticals, Inc. (SUPN) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by 7.66%.
Revenue Estimates for FY2025
Revise Upward
+1.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+167.62%
In Past 3 Month
Stock Price
Go Up
+7.66%
In Past 3 Month
5 Analyst Rating
30.40% Upside
Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 59.20 USD with a low forecast of 43.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
30.40% Upside
Current: 45.400
Low
43.00
Averages
59.20
High
65.00
30.40% Upside
Current: 45.400
Low
43.00
Averages
59.20
High
65.00
BofA
initiated
$65
2025-10-29
Reason
BofA
Price Target
$65
2025-10-29
initiated
Reason
BofA initiated coverage of Supernus with a Buy rating and $65 price target, citing what it sees as the "underappreciated" branded central nervous system growth drivers with its treatments for ADHD and motor complications in advanced Parkinson's disease. Qelbree offers a differentiated non-stimulant that continues to capture share both from patients new to treatment and those switching from other therapies, while Onapgo has "impressed" in its first quarter on the market, the analyst tells investors.
TD Cowen
TD Cowen
Buy
upgrade
$45 -> $60
2025-10-23
Reason
TD Cowen
TD Cowen
Price Target
$45 -> $60
2025-10-23
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Supernus to $60 from $45 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results. They said Onapgo's initial adoption is exceeding expectations, and expect sales of $8MM in Q3 and $23MM for 2025 which could be potentially conservative. Qelbree adoption is progressing well, and raised its 2025 sales estimate to $310MM. Zurzuvae to add to solid ongoing launches.
Cantor Fitzgerald
Overweight
maintain
$46 -> $63
2025-09-30
Reason
Cantor Fitzgerald
Price Target
$46 -> $63
2025-09-30
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Supernus to $63 from $46 and keeps an Overweight rating on the shares. The firm updated its model for ONAPGO to factor in a faster cadence of patients on therapy that slightly increases its peak sales potential. Cantor believes there may be even more upside beyond its ONAPGO estimates at this time, the analyst tells investors in a research note.
Piper Sandler
Neutral
maintain
$36 -> $40
2025-08-29
Reason
Piper Sandler
Price Target
$36 -> $40
2025-08-29
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Supernus to $40 from $36 and keeps a Neutral rating on the shares. Though the firm does wonder if there is more room for multiple expansion given the company's longer-term LOE exposure, Piper does concede that Onapgo, an infusion pump that provides continuous subcutaneous delivery of apomorphine for patients with advanced Parkinson's disease, is off to a strong start and bears watching as an upside driver.
Cantor Fitzgerald
Neutral -> Overweight
upgrade
$36 -> $42
2025-07-29
Reason
Cantor Fitzgerald
Price Target
$36 -> $42
2025-07-29
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald upgraded Supernus to Overweight from Neutral with a price target of $42, up from $36.
Cantor Fitzgerald
Kristen Kluska
Neutral -> Overweight
upgrade
$36 -> $42
2025-07-29
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$36 -> $42
2025-07-29
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald analyst Kristen Kluska upgraded Supernus to Overweight from Neutral with a price target of $42, up from $36. The firm believes Qelbree is redefining the treatment landscape for attention-deficit/hyperactivity disorder. The analyst cites a more positive outlook on Qelbree following its 25 physician survey for the upgrade. Cantor says 72% of those surveyed indicated they plan to prescribe more non-stimulants in the future, and it believes Qelbree could be a big part of this growth.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN.O) is 16.02, compared to its 5-year average forward P/E of 21.56. For a more detailed relative valuation and DCF analysis to assess Supernus Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
21.56
Current PE
16.02
Overvalued PE
27.51
Undervalued PE
15.61
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
13.52
Current EV/EBITDA
12.18
Overvalued EV/EBITDA
19.45
Undervalued EV/EBITDA
7.58
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.23
Current PS
44.62
Overvalued PS
7.95
Undervalued PS
-1.49
Financials
Annual
Quarterly
FY2025Q3
YoY :
+7.41%
188.71M
Total Revenue
FY2025Q3
YoY :
-259.75%
-63.63M
Operating Profit
FY2025Q3
YoY :
-217.20%
-45.12M
Net Income after Tax
FY2025Q3
YoY :
-215.94%
-0.80
EPS - Diluted
FY2025Q3
YoY :
-215.89%
-61.79M
Free Cash Flow
FY2025Q3
YoY :
-2.33%
77.06
Gross Profit Margin - %
FY2025Q3
YoY :
-59.57%
10.67
FCF Margin - %
FY2025Q3
YoY :
-209.13%
-23.91
Net Margin - %
FY2025Q3
YoY :
-100.00%
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
12.5M
USD
11
3-6
Months
9.5M
USD
12
6-9
Months
0.0
USD
0
0-12
Months
1.3M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 146.58% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
520.7K
Volume
Months
0-12
2
211.2K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
12.5M
USD
11
3-6
Months
9.5M
USD
12
6-9
Months
0.0
USD
0
0-12
Months
1.3M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SUPN News & Events
Events Timeline
2025-11-04 (ET)
2025-11-04
17:32:09
Supernus increases FY25 revenue forecast to $685M-$705M, up from $670M-$700M
2025-11-04
17:30:23
Supernus announces Q3 earnings per share of 80 cents, up from 69 cents last year.
2025-08-05 (ET)
2025-08-05
16:35:41
Supernus reports Q2 EPS 40c vs. 36c last year
Sign Up For More Events
Sign Up For More Events
News
2.0
10-31NASDAQ.COMBiotech Stocks Reach 52-Week Peaks: MTSR, INSM, ABVX, and MAZE Drive Surge on October 30
6.0
10-29CNBCKey Analyst Recommendations for Wednesday: Nvidia, Apple, Tesla, Victoria's Secret, Wayfair, Palantir, Datadog, and Others
4.0
10-29BenzingaB of A Securities Begins Coverage of Supernus Pharmaceuticals with a Buy Rating and Sets Price Target at $65
Sign Up For More News
People Also Watch
XTLB
X T L Biopharmaceuticals Ltd
0.931
USD
-1.17%
CLOV
Clover Health Investments Corp
2.430
USD
-1.62%
EVTC
Evertec Inc
29.360
USD
-0.24%
UFPT
UFP Technologies Inc
235.210
USD
+0.39%
BTE
Baytex Energy Corp
3.145
USD
+0.16%
OSW
Onespaworld Holdings Ltd
20.625
USD
-2.39%
CRTO
Criteo SA
21.360
USD
-0.88%
INTR
Inter & Co Inc
9.190
USD
-0.33%
OFG
OFG Bancorp
40.280
USD
-1.08%
BKV
BKV Corp
27.770
USD
+4.40%
FAQ
What is Supernus Pharmaceuticals Inc (SUPN) stock price today?
The current price of SUPN is 45.4 USD — it has increased 2.16 % in the last trading day.
What is Supernus Pharmaceuticals Inc (SUPN)'s business?
What is the price predicton of SUPN Stock?
What is Supernus Pharmaceuticals Inc (SUPN)'s revenue for the last quarter?
What is Supernus Pharmaceuticals Inc (SUPN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Supernus Pharmaceuticals Inc (SUPN)'s fundamentals?
How many employees does Supernus Pharmaceuticals Inc (SUPN). have?